内科理论与实践 ›› 2022, Vol. 17 ›› Issue (01): 48-52.doi: 10.16138/j.1673-6087.2022.01.009
于颖彦
收稿日期:2021-10-29
出版日期:2022-02-28
发布日期:2022-07-25
基金资助:
Received:2021-10-29
Online:2022-02-28
Published:2022-07-25
中图分类号:
于颖彦. 免疫检查点及其抑制剂的发展[J]. 内科理论与实践, 2022, 17(01): 48-52.
表1
肿瘤相关免疫检查点、配体及其表达细胞
| T细胞受体 | 配体表达 | ||
|---|---|---|---|
| 抗原提呈细胞 | 肿瘤细胞 | 其他细胞 | |
| CTLA4（CD152） | CD80（B7-1）、CD86（B7-2） | ||
| PD1（CD279） | PD-L1（CD274）、PD-L2（B7-DC） | ||
| TIM-3（HAVCR2） | GAL-9 | CEACAM1、HMGB1 PS | |
| TIGIT（VSIG9） | CD155（PVR）、CD112（PVRL2） | 巨噬细胞 | |
| LAG-3（CD223） | MHC-Ⅱ | MHC-Ⅱ、FGL1 | 肝窦间隙内皮细胞 |
| BTLA | HVEM（TNFRSF14） | ||
| VISTA（PD1-H） | VSIG3、PSGL-1、VISTA | VISTA未知 | 胎盘 |
| 未知 | B7-H3（CD276）/B7-H4（B7S1） | B7-H3（CD276）/B7-H4（B7S1） | 内皮细胞 |
| 未知 | SIGLEC15 | 肿瘤浸润髓细胞 破骨细胞,巨噬细胞 | |
| AHR | IDO1代谢物KYN | IDO1代谢物KYN | 单核细胞,巨噬细胞 |
| [1] |
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition[J]. Nat Rev Immunol, 2013, 13(4): 227-242.
doi: 10.1038/nri3405 URL |
| [2] | Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma[J]. J Dtsch Dermatol Ges, 2011, 9(4): 277-286. |
| [3] |
Zhai Y, Moosavi R, Chen M. Immune checkpoints, a novel class of therapeutic targets for autoimmune diseases[J]. Front Immunol, 2021, 12: 645699.
doi: 10.3389/fimmu.2021.645699 URL |
| [4] |
Xiang Z, Zhou Z, Song S, et al. Dexamethasone suppresses immune evasion by inducing GR/STAT 3 mediated downregulation of PD-L1 and IDO1 pathways[J]. Oncogene, 2021, 40(31): 5002-5012.
doi: 10.1038/s41388-021-01897-0 pmid: 34175886 |
| [5] |
Zahavi DJ, Weiner LM. Targeting multiple receptors to increase checkpoint blockade efficacy[J]. Int J Mol Sci, 2019, 20(1): 158.
doi: 10.3390/ijms20010158 URL |
| [6] |
Hernández áP, Juanes-Velasco P, Landeira-Viñuela A, et al. Restoring the immunity in the tumor microenvironment: insights into immunogenic cell death in onco-therapies[J]. Cancers (Basel), 2021, 13(11): 2821.
doi: 10.3390/cancers13112821 URL |
| [7] |
Muller AJ, Manfredi MG, Zakharia Y, et al. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond[J]. Semin Immunopathol, 2019, 41(1): 41-48.
doi: 10.1007/s00281-018-0702-0 URL |
| [8] |
Wang J, Sun J, Liu LN, et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy[J]. Nat Med, 2019, 25(4): 656-666.
doi: 10.1038/s41591-019-0374-x pmid: 30833750 |
| [9] |
Ren X. Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle[J]. Cancer Biol Med, 2019, 16(2): 205-210.
doi: 10.20892/j.issn.2095-3941.2018.0141 URL |
| [10] |
Mathieu L, Shah S, Pai-Scherf L, et al. FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer[J]. Oncologist, 2021, 26(5): 433-438.
doi: 10.1002/onco.13752 URL |
| [11] |
Kaplon H, Reichert JM. Antibodies to watch in 2019[J]. MAbs, 2019, 11(2): 219-238.
doi: 10.1080/19420862.2018.1556465 URL |
| [12] |
Keam SJ. Toripalimab: first global approval[J]. Drugs, 2019, 79(5): 573-578.
doi: 10.1007/s40265-019-01076-2 URL |
| [13] |
Zhang Y, Li X, Sun Y, et al. Pharmacokinetics of S-epacadostat, an indoleamine 2,3-dioxygenase 1 inhibitor, in dog plasma and identification of its metabolites in vivo and in vitro[J]. Biomed Chromatogr, 2021, 35(12); e5226.
doi: 10.1002/bmc.5226 pmid: 34388261 |
| [14] |
Shi JG, Bowman KJ, Chen X, et al. Population pharmacokinetic and pharmacodynamic modeling of epacadostat in patients with advanced solid malignancies[J]. J Clin Pharmacol, 2017, 57(6): 720-729.
doi: 10.1002/jcph.855 URL |
| [15] |
Yu Y. Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers[J]. Cancer Biol Med, 2021, 18 (4): 944-948.
doi: 10.20892/j.issn.2095-3941.2021.0491 URL |
| [16] |
Fattakhova E, Hofer J, DiFlumeri J, et al. Identification of the FDA-approved drug pyrvinium as a small-molecule inhibitor of the PD-1/PD-L1 interaction[J]. ChemMedChem, 2021, 16(18): 2769-2774.
doi: 10.1002/cmdc.202100264 URL |
| [17] |
Han N, Hwang W, Tzelepis K, et al. Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies[J]. Sci Adv, 2021, 7(27): eabh3032.
doi: 10.1126/sciadv.abh3032 URL |
| [18] |
Bronte G, Verlicchi A, De Matteis S, et al. Circulating myeloid-derived suppressive-like cells and exhausted immune cells in non-small cell lung cancer patients treated with three immune checkpoint inhibitors[J]. Front Immunol, 2021, 12: 672219.
doi: 10.3389/fimmu.2021.672219 URL |
| [19] |
Takahashi A, Namikawa K, Ogata D, et al. Real-world efficacy and safety data of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma[J]. J Dermatol, 2020, 47(11): 1267-1275.
doi: 10.1111/1346-8138.15521 URL |
| [20] |
Gaudreau PO, Lee JJ, Heymach JV, et al. Phase Ⅰ/Ⅱ trial of immunotherapy with durvalumab and tremelimumab with continuous or intermittent MEK inhibitor selumetinib in NSCLC[J]. Clin Lung Cancer, 2020, 21(4): 384-388.
doi: 10.1016/j.cllc.2020.02.019 URL |
| [21] |
Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma[J]. J Clin Oncol, 2017, 35(34): 3851-3858.
doi: 10.1200/JCO.2016.72.1985 pmid: 28678668 |
| [22] |
McGregor BA, Campbell MT, Xie W, et al. Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies[J]. Cancer, 2021, 127(6): 840-849.
doi: 10.1002/cncr.33328 URL |
| [23] |
Ebata T, Shimizu T, Fujiwara Y, et al. Phase Ⅰ study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours[J]. Invest New Drugs, 2020, 38(2): 468-477.
doi: 10.1007/s10637-019-00787-3 URL |
| [24] |
Jung KH, LoRusso P, Burris H, et al. Phase Ⅰ study of the indoleamine 2,3-dioxygenase 1(IDO1) inhibitor navoximod (GDC-0919) administered with PD-L1 inhibitor (atezolizumab) in advanced solid tumors[J]. Clin Cancer Res, 2019, 25: 3220-3228.
doi: 10.1158/1078-0432.CCR-18-2740 URL |
| [25] |
Hollebecque A, Chung HC, de Miguel MJ, et al. Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors[J]. Clin Cancer Res, 2021, 27(23): 6393-6404.
doi: 10.1158/1078-0432.CCR-21-0261 pmid: 34465599 |
| [26] |
Atkinson V, Khattak A, Haydon A, et al. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma[J]. J Immunother Cancer, 2020, 8(2): e001681.
doi: 10.1136/jitc-2020-001681 URL |
| [27] |
De Luca AJ, Lyons AB, Flies AS. Cytokines: signalling improved immunotherapy?[J]. Curr Oncol Rep, 2021, 23(9): 103.
doi: 10.1007/s11912-021-01095-x URL |
| [28] |
Shibata Y, Murakami S, Kato T. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors[J]. Expert Opin Drug Saf, 2021, 20(5): 537-547.
doi: 10.1080/14740338.2021.1898584 URL |
| [29] |
Cunningham M, Iafolla M, Kanjanapan Y, et al. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy[J]. PLoS One, 2021, 16(6): e0253070.
doi: 10.1371/journal.pone.0253070 URL |
| [1] | 朱芳 徐喆 王先明 宋达疆 李赞 何建怀 屈洪波. 乳腺癌根治术后即刻行扩大背阔肌肌皮瓣乳房再造50例分析[J]. 组织工程与重建外科杂志, 2022, 18(5): 377-. |
| [2] | 刘淼, 沈燕, 傅晓红, 胡姣姣, 陈庆庆, 应涛. 常规超声和超声造影检查不同大小病灶乳腺癌的比较研究[J]. 外科理论与实践, 2022, 27(3): 229-233. |
| [3] | 钟民衎 崔锡炜 顾斌 李青峰 王智超. Ⅰ型神经纤维瘤病相关眼眶-眶周型丛状神经纤维瘤的临床治疗进展[J]. 组织工程与重建外科杂志, 2022, 18(2): 179-. |
| [4] | 潘睿忻 综述, 陈小松, 沈坤炜 审校. 循环肿瘤DNA和循环肿瘤细胞检测乳腺癌微小残留病灶的研究[J]. 外科理论与实践, 2022, 27(05): 463-467. |
| [5] | 马雪菲, 王学锋, 王侃侃. 浆细胞瘤变异体易位1和MYC基因在泛癌中的表达及生存期预测价值分析[J]. 诊断学理论与实践, 2022, 21(04): 490-496. |
| [6] | 何新, 陈慧, 冯炜炜. 机器学习算法在辅助超声诊断附件肿块良恶性中的应用研究进展[J]. 诊断学理论与实践, 2022, 21(04): 541-546. |
| [7] | 车稳, 柳蒋书, 陈晓炎, 王朝夫, 袁菲, 王璇. 肺混合性鳞状细胞和腺性乳头状瘤2例临床病理特征及冷冻切片病理诊断误诊分析[J]. 诊断学理论与实践, 2022, 21(04): 476-481. |
| [8] | 李为光, 孙蕴伟, 孙菁, 张本炎, 王华枫, 钱爱华. 直径≤1 cm的直肠神经分泌肿瘤2种内镜治疗方法的比较[J]. 内科理论与实践, 2022, 17(04): 289-294. |
| [9] | 郭良奇, 严志龙, 张谋成. 腹腔镜经胃腔手术治疗胃黏膜下肿瘤和早期胃癌[J]. 外科理论与实践, 2022, 27(04): 380-383. |
| [10] | 汤钊猷. 中华哲学思维对肝癌治疗的启迪[J]. 外科理论与实践, 2022, 27(02): 93-94. |
| [11] | 张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157. |
| [12] | 管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184. |
| [13] | 杨伯文, 姜美娇, 陈慧. 超声IOTA简单法鉴别诊断卵巢肿瘤良恶性的临床研究[J]. 诊断学理论与实践, 2022, 21(01): 74-79. |
| [14] | 史逸华, 吉顺荣, 徐晓武, 虞先濬. 保留功能的微创胰腺肿瘤剜除术技术要点及思考[J]. 外科理论与实践, 2022, 27(01): 14-18. |
| [15] | 李骥, 傅德良, 倪泉兴. 胰腺囊性肿瘤的手术干预决策与局部剜除术[J]. 外科理论与实践, 2022, 27(01): 19-21. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
